Skip to main content

Advertisement

SpringerLink
Log in

Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes

  • Original Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

Bevacizumab is a humanized monoclonal antibody that blocks vascular endothelial factor. It demonstrated an efficacy in many cancer types. The standard recommendation of administration is the 90-, 60-, and 30-min infusion sequence for all doses. We evaluated in this study the possibility of reducing infusion time to 10 min for bevacizumab given at 5 or 7.5 mg/kg in metastatic colorectal cancer (MCRC).

Patients and Methods

All patients who received bevacizumab for MCRC were analyzed. Patients were divided into two groups: Group A (bevacizumab was given in the 90-, 60-, and 30-min infusion sequence) and group B (bevacizumab was given over 10 min). Patients’ medical records were used to identify any hypersensitivity reactions (HSR) possibly related to bevacizumab.

Results

There were 38 patients in group A and 43 in group B. In group A, 459 doses of bevacizumab were given (286 doses at 5 mg/kg and 173 doses at 7.5 mg/kg). No HSR occurred in this group. In group B, 527 doses of bevacizumab were given (335 doses at 5 mg/kg and 192 doses at 7.5 mg/kg). Only two events of HSR grade 2 were reported in the 7.5 mg/kg infusions. Both of them were easily resolved with symptomatic treatment.

Conclusions

Bevacizumab 5 or 7.5 mg/kg in MCRC can be infused safely over 10 min.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

FOLFOX:

leucovorin, fluorouracil, and oxaliplatin

FOLFIRI:

leucovorin, fluorouracil, and irinotecan

XELOX:

capecitabine and oxaliplatin

XELIRI:

capecitabine and irinotecan

References

  1. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999;59:5209–18.

    PubMed  CAS  Google Scholar 

  2. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841–4.

    Article  PubMed  CAS  Google Scholar 

  3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.

    Article  PubMed  CAS  Google Scholar 

  4. Giantonio BJ, Catalano PJ, Meropol NJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. ASCO Annual Meeting. Abstract no: 2, 2005.

  5. Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006;355:2542–50.

    Article  PubMed  CAS  Google Scholar 

  6. Reck M, Von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol. 2009;27:1227–34.

    Article  PubMed  CAS  Google Scholar 

  7. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.

    Article  PubMed  CAS  Google Scholar 

  8. Miles D, Chan D, Romieu G et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. ASCO Annual Meeting. Abstract No 1011, 2008

  9. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). ASCO Annual Meeting. Abstract No 1005, 2009.

  10. Escudier B, Pluzanska A, Koralewski P, et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet. 2007;370:2103–11.

    Article  PubMed  Google Scholar 

  11. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone or in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;25:4733–40.

    Article  Google Scholar 

  12. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740–5.

    Article  PubMed  CAS  Google Scholar 

  13. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697–705.

    Article  PubMed  CAS  Google Scholar 

  14. Giantonio BJ, Catalano PF, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44.

    Article  PubMed  CAS  Google Scholar 

  15. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.

    Article  PubMed  CAS  Google Scholar 

  16. Reidy DL, Chung KY, Timoney JP, et al. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol. 2007;25:2691–5.

    Article  PubMed  CAS  Google Scholar 

  17. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–81.

    Article  PubMed  Google Scholar 

  18. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–5.

    Article  PubMed  CAS  Google Scholar 

  19. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792–9.

    Article  PubMed  CAS  Google Scholar 

  20. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–26.

    Article  PubMed  CAS  Google Scholar 

  21. Foran JM, Cunningham D, Coiffier B, et al. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol. 2000;11:117–21.

    Article  PubMed  Google Scholar 

  22. Hallek M, Fingerle-Rowson G, Fink AM. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). ASH. Abstract No 325, 2008.

Download references

Acknowledgments

We sincerely thank Mr. Seddik Ouboulahcen and Miss Nada Mahfoud for their linguistic assistance.

Conflict of Interest

The authors declare that they have no conflict of interest.

Consent and Statement of Ethical Approval

This study was approved by the ethics committee of the military hospital in Rabat.

All patients gave their informed consent prior to their inclusion in the study.

Authors’ Contributions

All authors have made significant contributions by making diagnosis, treatment, and intellectual input in this study and writing the manuscript. All authors read and approved the final manuscript.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Military Hospital Mohammed V, Rabat, Morocco

    Tarik Mahfoud, Rachid Tanz, Mohamed Réda Khmamouche, Aziz Bazine & Mohamed Ichou

  2. Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco

    Tarik Mahfoud, Mohamed Mesmoudi, Rachid Aassab, Nabil Ismaili, Saber Boutayeb & Hassan Errihani

Authors
  1. Tarik Mahfoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachid Tanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed Mesmoudi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohamed Réda Khmamouche
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aziz Bazine
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rachid Aassab
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nabil Ismaili
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Saber Boutayeb
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mohamed Ichou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hassan Errihani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tarik Mahfoud.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mahfoud, T., Tanz, R., Mesmoudi, M. et al. Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes. J Gastrointest Canc 43, 244–248 (2012). https://doi.org/10.1007/s12029-010-9245-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-010-9245-x

Keywords

Search

Navigation